J.P. Morgan analyst Casey Woodring has maintained their bullish stance on DHR stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Casey Woodring has given his Buy rating due to a combination of factors that highlight Danaher’s strong performance and future potential. The company reported a notable beat in both top- and bottom-line figures for the third quarter, with non-GAAP core growth surpassing expectations. This was largely driven by impressive growth in the Biotechnology segment, particularly in bioprocessing, which has shown consistent high single-digit growth for four consecutive quarters.
Furthermore, Danaher’s strategic investments in productivity, amounting to over $150 million, are expected to enhance earnings in 2026. Despite a lowered guidance for 2025, these investments and the company’s ability to maintain robust growth in key areas like Biotechnology suggest a positive outlook. Woodring believes that these factors, combined with Danaher’s strong execution and strategic positioning, justify a Buy rating for the stock.
In another report released today, Bank of America Securities also maintained a Buy rating on the stock with a $240.00 price target.